Abstract
161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
